Actualités

Strong sales of blood thinner Eliquis and newer drugs Camzyos and Reblozyl pushed second-quarter revenue to $12.97 billion, above analyst estimates

Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. Pfizer Value Investment Play Pfizer (NYSE:PFE) has seen its valuation drop […]

Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.

European Commission grants marketing authorization for Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for the 2026-2027 season in the EU. Approval covers use in individuals aged 6 months and older across all EU member states. Authorization supports advance manufacturing and supply ahead of the upcoming respiratory disease season. Pfizer, listed as NYSE:PFE, now has European Commission authorization for its XFG-adapted COVID-19 vaccine for the 2026-2027 season. The decision confirms that...

The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.

MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.

Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Not every fat dividend yield is worth chasing into retirement, and the difference between a durable income stream and a yield trap often hides in details most investors skip past entirely.

Retirement means living off your portfolio, not waiting for it to grow, and right now five familiar dividend giants are trading at prices that Wall Street considers deeply undervalued.

In the most recent trading session, Pfizer (PFE) closed at $25.25, indicating a +2.35% shift from the previous trading day.

Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.

One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.

Rep. Thomas Massie (R-Ky.) questioned Vice President JD Vance‘s silence after the Trump administration established billions for Pfizer Inc.‘s COVID-19 vaccine contracts for 2026 and 2027. On Sunday, Massie revived Vance’s COVID vaccine comments from the Joe Rogan podcast in...

AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms it.

Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OPKO Health Inc (OPK) reports significant revenue growth in pharmaceuticals and a notable reduction in net loss, despite challenges in diagnostics.

The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.

Inspectors issue stop-work order at planned 32-story apartment tower in Manhattan, carrying out safety sweeps after former Pfizer headquarters building buckled.

BMY heads into Q2 earnings with growth drugs driving momentum as legacy products decline, setting the stage for a closely watched earnings report.

Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.

VRTX heads into its Q2 earnings release with Trikafta, Alyftrek, Casgevy and Journavx in focus as investors watch product sales and updates on ongoing pipeline studies.

Earlier this month, Pfizer announced that the FDA accepted for Priority Review a supplemental application for TALZENNA in combination with XTANDI to treat men with HRR gene‑altered metastatic castration‑sensitive prostate cancer, supported by positive Phase 3 TALAPRO‑3 results and existing approvals for later‑stage disease. This move could broaden Pfizer’s prostate cancer franchise into an earlier disease setting, potentially deepening its footprint in precision oncology and expanding the...

The company that used to reassure you with its sheer breadth now leads with a push to dominate oncology, and a holder who bought a diversified compounder should notice the bet has changed shape.

Far from "yield traps," these high-yield dividend stocks represent good value at current prices.

(Bloomberg) -- Investors will soon have another way to bet on the hottest stocks from Nvidia Corp. to SpaceX, without trading a single share.Most Read from BloombergDeepSeek Said to Tell Backers of Funding Pause After Viral PostsSpaceX at $100 Would Imply Zero AI Value, Morgan Stanley SaysTrump Seethes as Iran War Spirals Anew With No End in SightHouthis Claim Saudi Attack as US Ends Run of Iran StrikesRetina Chip Designed to Restore Sight to Go on Sale in EuropeCME Group Inc. will launch single

(Bloomberg) -- Investors will soon have another way to bet on the hottest stocks from Nvidia Corp. to SpaceX, without trading a single share.Most Read from BloombergDeepSeek Said to Tell Backers of Funding Pause After Viral PostsSpaceX at $100 Would Imply Zero AI Value, Morgan Stanley SaysTrump Seethes as Iran War Spirals Anew With No End in SightHouthis Claim Saudi Attack as US Ends Run of Iran StrikesRetina Chip Designed to Restore Sight to Go on Sale in EuropeCME Group Inc. will launch single

Management's plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.

Pfizer has a 6.8% yield at a time when the market's yield is roughly 1%: Is there something wrong?